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Abstract
Cardiovascular (CV) engagement in coronavirus disease 2019 (COVID-19) is a huge determinant of prognosis during the acute
phase of the disease. However, little is known about the potential chronic implications of the late phase of COVID-19 and
about the appropriate approach to these patients. Heart failure, type 1 and type 2 myocardial infarction, arrhythmias, myo-
carditis, pulmonary fibrosis, and thrombosis have been shown to be related to severe acute respiratory syndrome coronavirus
2 infection, and a ‘long COVID-19’ illness has been recognized with fatigue, chest pain, and dyspnoea among the most frequent
symptoms reported after discharge from hospital. This paper focuses on some open questions that cardiologists are going to
face during the next months in a general cardiology outpatient clinic, in particular how to evaluate a ‘post-COVID’ patient dur-
ing follow-up of CV complications of the acute phase and how to manage new CV symptoms that could be the consequence, at
least in part, of heart/vessels and/or lung involvement of the previous virus infection. Present symptoms and signs, history of
previous CV disease (both preceding COVID-19 and occurring during viral infection), and specific laboratory and imaging mea-
surements during the acute phase may be of interest in focusing on how to approach the clinical evaluation of a post-COVID
patient and how to integrate in our standard of care the new information on COVID-19, possibly in a multidisciplinary view.
Dealing with the increased COVID-associated CV risk burden and becoming acquainted with potential new e-cardiology
approaches aimed at integrating the cardiology practice are relevant new challenges brought by severe acute respiratory
syndrome coronavirus 2 infection and its sequelae.
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Introduction
Severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2)
causing coronavirus disease 2019 (COVID-19) has reached pan-
demic levels since March 2020. SARS-CoV-2 not only causes vi-
ral pneumonia but also has major implications on various
systems. Different clinical aspects of general cardiology and in-
ternal medicine, including lung, kidney, liver, and cerebral
complications mimicking a cardiac, vascular, or complex
multisystem pathology and unusual presentations, have been
shown to be related to SARS-CoV-2 infection.1–4
Intricate interactions among systems may occur upon virus
infection. Immunological disorders and inappropriate im-
mune activation with during systemic inflammatory response
may lead to altered peripheral resistance and microvascular
dysfunction, endothelial injury, abnormal thrombo-embolic
balance, plaque instability, and myocardial damage.5,6 Acute
lung parenchymal injury, lung inflammation, leading to
ESC AND HFA PAPER
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
ESC HEART FAILURE
ESC Heart Failure 2021; 8: 3483–3494
Published online 25 June 2021 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.13466
micro-vessel thrombosis and dysfunction, and hypoxemia7,8
entail an increased cardiac workload. This deleterious impact
on cardiac function, especially in patients with pre-existing
clinical or subclinical heart failure (HF), may further impair
peripheral tissues and renal perfusion.7
Myocarditis due to the generalized inflammatory reaction
plays an important role in patients with acute HF aside from
arterial and venous thrombotic complications presenting as
acute coronary syndromes (both myocardial infarction type
1 and type 2), venous thrombo-embolism (VTE), and pulmo-
nary embolism.7,9,10 Other expressions of cardiac injury may
be a takotsubo syndrome or a Kawasaki-like syndrome,
whereas a direct virus involvement in cardiomyocyte damage
has not yet been reported.11–14 A wide range of arrhythmias
has been reported to complicate the course of COVID-19 in-
cluding potential pro-arrhythmic effects of medical treatment
targeted at COVID-19 used during the first months of
pandemic.10
Patients with cardiovascular (CV) risk factors including male
sex, advanced age, diabetes, hypertension, and obesity and
patients with established CV and cerebrovascular disease have
been identified as particularly vulnerable populations with
increased morbidity and mortality,7,15 mainly in-hospital
mortality.
Although COVID-19 has a direct involvement with the CV
system, an apparent worldwide reduction of acute coronary
events during the COVID pandemic has been observed. Vari-
ous studies have found that the incidence of hospitalization
for acute myocardial infarction and admissions for HF have
decreased during the pandemic.16–19 Possible underestima-
tion of symptoms in community and/or prevailing urgencies
associated with overwhelming pandemic in hospital prevent
patients from optimal treatment of acute CV disease. Possible
explanations for the decreased hospitalization rate include
patient fear of being infected if hospitalized (avoidance of
medical care) and a redistribution of health care.
Late phase of coronavirus disease
2019: how to approach the clinical
evaluation of a post-coronavirus
disease 2019 patient
In the late post-COVID-19 phase, cardiologists might be inter-
ested in surveillance of previously detected abnormalities
(during the acute phase) to follow-up the potential recovery
or progression of disease. Continuous control and surveil-
lance strategies in these patients should be based on the se-
verity of clinical presentation, as well as on completeness of
pre-discharge clinical and imaging workout. Possibly, a
follow-up should be planned before discharge from hospital,
focusing on a cardiological follow-up in the patients with
cardiac diseases diagnosed before or during the acute
COVID-related hospital stay. Evidence is growing that many
patients have long-lasting effects of SARS-CoV-2 infection
and a ‘long COVID-19’ illness has been recognized,20–25 and
studies involving several countries are ongoing to focus on
late COVID sequelae.26
In patients without CV involvement during the acute phase,
cardiologists may be called to assess subacute and chronic
clinical pictures of COVID-19-related CV disease. These may
include more specific, concerning symptoms (i.e. new signs
of HF, typical chest pain, and palpitations) or vague,
non-specific complains such as fatigue, weakness, shortness
of breath, or cough. Fatigue, chest pain, and dyspnoea to-
gether with sleep difficulties and anxiety/depression are
among the most reported symptoms weeks after discharge
from hospital after an acute phase of COVID-19.20–22,27 Acute
disease severity was the most relevant predictor of symptoms
at 6 months after COVID onset, and therefore, patients who
are more severely ill during their hospital stay seem to be
the main target for a tight follow-up after discharge.27
Therefore, post-COVID-19 patients will be referred to the
general cardiologist office because of (i) follow-up of CV in-
volvement diagnosed during the acute phase or (ii) CV com-
plains occurring in the late phase or long-lasting symptoms.
Patients with acute cardiovascular complications
during acute coronavirus disease 2019 follow-up
Patients with acute COVID-19-associated CV complications
should be followed and checked with a complete clinical
evaluation and managed as patients with acute non-COVID
19-associated CV events with some specific suggestions listed
in Table 1.
Myocardial injury in acute COVID-19 may be diagnosed by
elevated serum biomarkers, in particular high-sensitivity car-
diac troponin T/I (Tn) concentrations, and cardiac
imaging.7,9,28,29 In early studies of the COVID-19 pandemic,
20–35% of hospitalized COVID-19 patients had elevated car-
diac biomarker levels (i.e. Tn and natriuretic peptides: B-type
natriuretic peptide and N-terminal pro-B-type natriuretic pep-
tide). These alterations have been associated with increased
mortality rate.9,28,30 Very high Tn levels seem useful to distin-
guish specific cardiac disease during acute COVID from myo-
cardial cell involvement associated to viral injury added on
top of previous cardiac disease (Tn levels up to three times
above the upper limit of the normal value; see figure 11 of
the European Society of Cardiology document on acute
COVID-19 referenced as number 7).7,31
Cardiac abnormalities were observed in half of all
COVID-19 patients undergoing echocardiographic studies,
which have demonstrated primarily left ventricular (LV) pre-
served ejection fraction and LV diastolic dysfunction associ-
ated with right ventricular (RV) abnormalities as common
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abnormalities.28,32,33 In a prospective international
multicentre study enrolling 1216 patients with presumed
COVID-19, 667 patients (55%) had an abnormal echocardio-
gram. Severe cardiac disease (severe ventricular dysfunction
or tamponade) was observed in 182 patients (15%). In 901
patients without pre-existing cardiac disease, the echocardio-
gram was abnormal in 46%, and 13% had severe disease.
Independent predictors of LV and RV abnormalities were dis-
tinct, including elevated natriuretic peptides for the former
and severity of COVID-19 symptoms for the latter.33,34 Abnor-
mal increase in ascending aorta and left atrial enlargement
were found to be associated with severe inflammation and
cardiac injury.35
When assessing patients with acute COVID-19-associated
acute CV complications, it should be kept in mind that there
may be long-term cardiac effects of COVID-19 infection.9,28
First, it is possible that an acute cardiac event may be the pre-
cipitating factor of a pre-existing, but previously asymptom-
atic, subclinical HF to a symptomatic HF. Second, it could be
theoretically possible that a persistent myocardial damage
caused by SARS-CoV2 infection may increase the future risk
of an overt decompensation. Finally, many survivors of severe
acute COVID-19 will be at risk for chronic right HF, pulmonary
hypertension, and diastolic dysfunction, secondary to myo-
cardial impairment during the acute phase and as a result
of chronic pulmonary disease.9,28,36–38 Moreover, considering
the high prevalence of pre-existing hypertension in COVID-19
patients, it is possible that a proportion of the population
exhibited pre-existing LV hypertrophy associated with
diastolic dysfunction.39 The occurrence of arrhythmias, in
particular atrial fibrillation, during the acute phase is a fre-
quent observation.10 New-onset atrial fibrillation in sepsis is
associated with increased stroke and mortality.40 It could be
advisable to perform a Holter electrocardiogram (ECG) moni-
toring and transthoracic echocardiography (TTE) as soon as
possible in patients with arrhythmias in the acute phase,
together with laboratory evaluation of electrolyte and
hormonal disorders.
Taking into account safety issues, any imaging strategy
should be preceded by a comprehensive clinical evaluation in-
cluding clinical history of the time of hospitalization and con-
temporary clinical history, physical examination, 12-lead ECG,
and blood tests possibly including cardiac biomarkers. If
diagnostic workout protocols including imaging had been
terminated during the in-hospital phase, patients should be
followed as suggested by current clinical guidelines. Other-
wise, the same guidelines should be used to complete missing
diagnostic steps. For myocarditis, TTE is a first-line imaging
modality, followed by CV magnetic resonance (CMR) when
needed and with appropriate protocols, and including more
advanced imaging modalities (e.g. positron emission
tomography).41,42 Coronary computed tomography angiogra-
phy may be useful if coronary anatomy has to be assessed in
suspected coronary artery disease.43 If the functional evalua-
tion of coronary stenosis is clinically appropriate, particularly
if prevalence of active COVID-19 in the community is sup-
posed to be moderate to high, pharmacological stress is pre-
ferred over exercise, because of safety concerns. Associated
imaging modality should be used based on local expertise
and also on the individual safety considerations.36–38
Table 1 Clinical suggestions for patients who presented acute CV complication during acute COVID-19
Cardiovascular complications diagnosed during acute
COVID-19
Specific suggestions that should integrate a complete clinical
evaluation
If a clear diagnosis in relation with myocardial injury has
been performed in the acute phase
Acute myocardial infarction type 1
Coronary angiography if not performed in the acute phase as soon as
possible
Check for CV risk factors and treat accordingly
TTE
Acute myocardial infarction type 2
CCTA
Identify and treat underlying causes
Check for CV risk factors and treat accordingly
TTE
Myocarditis
TTE at 3 months in clinically stable patients
CRM if available at baseline or for differential diagnosis
Heart failure TTE at 3 months in clinically stable patients
Check for CV risk factors and treat accordingly
Arrhythmias Check for correctable risk factors (e.g. drug-associated prolonged QTc,
such as hydroxychloroquine, and electrolyte disorders)
Holter ECG and TTE as soon as possible
In persisting unexplained sinus tachycardia Consider TTE
Pulmonary embolism Check for temporary and permanent major and minor risk factor
Check for thrombophilia in young patients or concomitant unusual site
thrombosis
TTE: check for pulmonary hypertension at 3 months or prior if
symptoms
CCTA, coronary computed tomography angiography; COVID-19, coronavirus disease 2019; CMR, cardiovascular magnetic resonance; CV,
cardiovascular; ECG, electrocardiogram; TTE, transthoracic echocardiography.
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Possible cardiovascular symptoms and signs
occurring in the late phase
If new CV symptoms and/or persistence of symptoms after
recovery from the acute phase (both resting and
upon-effort dyspnoea, shortness of breath, chest pain,
tachycardia, and fatigue) or signs (peripheral oedema) occur
weeks/months after acute COVID-19, the suggestion is to
integrate the usual patient workout with the evaluation
detailed in Table 2.
The clinical history of acute COVID-19 manifestations to
be considered in an ambulatory CV setting is focused on
the severity of acute COVID-19 stages, Tn levels, acute phase
imaging data, and treatments for acute COVID-19, in order
to have insight on the potential myocardial injury and se-
quelae, lung involvement, and cytokine/thrombo-embolic
activation.7
The complete clinical examination is performed as usual,
with focus on the prevalent symptoms and on signs such as
heart rhythm, murmurs, abnormal breathing crepitus/noises
including velcro-like crackles (associated with interstitial lung
disease), peripheral oedema, and peripheral O2 saturation. If
available, elevated concentrations of B-type natriuretic
peptide/N-terminal pro-B-type natriuretic peptide in a
dyspnoeic post-COVID-19 patient might be helpful to assess
cardiac dysfunction or clinical HF, together with other clinical
signs, and justify the request for TTE as a first-line imaging
modality. However, to date, the utility of serum biomarkers
is undefined in the chronic phase.36–38
A 12-lead ECG should be always repeated and compared
with ECG of the acute phase if available. In an outpatient set-
ting, the echocardiogram has a central value in post-COVID-19
cardiac and lung signs/symptoms evaluation, to make
differential diagnosis of heart vs. lung involvement or mixed
implication (Figure 1). Once the prevalent lung involvement
in determining symptoms has been evidenced, a referral to
a specialist in lung diseases is indicated.
A possible role of exercise testing and cardiopulmonary exer-
cise testing in post-COVID patients may be considered for the
evaluation of maximal exercise capacity and cardiopulmonary
involvement44,45 provided the acute myocarditis has been ruled
out. Moreover, if a patient is not aware of a previous COVID-19
despite heart/lung involvement that may suggest a previous
SARS-CoV-2 infection, a serological evaluation aimed at
confirming or excluding a previous infection, together with re-
ferral to the general practitioner, may be advised.
Table 2 Clinical evaluation of patients with CV symptoms and/or signs in the late phase of COVID-19
Patient evaluation Check for
Clinical history - Severity of acute COVID-19 and related complications
- Tn levels and biomarker levels in the acute phase
- Imaging parameters at TTE, LUS, and lung CT scan in the acute phase
- Treatment for acute COVID-19 and related complications, in particular antithrombotic drugs,
antiviral agents, hydroxychloroquine, steroid, and other anti-inflammatory agents
Physical examination - Prevalent symptoms and signs




- LV septal thickness (transient septal pseudohypertrophy)
- LV ejection fraction
- Regional wall motion abnormalities (coronary or non-coronary pattern)
- LV strain if available
- LV diastolic function (comprehensive assessment)
- Valve morphology and function
Right ventricle
- RV size (EDD and RV area)
- RV geometry (e.g. sphericity index)
- RV systolic function global (RV strain if available) and regional (McConnell’s sign)
- Tricuspid regurgitant pulmonary gradient
- Pulmonary flow patterns (AcT and notching)
Pericardial evaluation and myopericardial brightness
Lung ultrasound - Interstitial syndrome (BLUE protocol)
- Integrative assessment of congestion in heart failure
Lung computed tomography - Lung parenchyma
- Patency of pulmonary arteries
- Patency of coronary arteries
- Myocardial damage
Cardiovascular magnetic resonance - Accurate assessment of chamber size and function
- Detection of ischaemia/myocardial infarction
- Assessment of myocarditis and stress cardiomyopathy
COVID-19, coronavirus disease 2019; CT, computed tomography; CV, cardiovascular; EDD, end-diastolic diameter; LUS, lung ultrasound;
LV, left ventricular; RV, right ventricular; Tn, high-sensitivity cardiac troponin T/I; TTE, transthoracic echocardiography.
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Heart and lung imaging
Echocardiogram
Left atrial and LV size and function should be carefully
assessed as well as regional wall motion abnormalities. If re-
gional wall motion abnormalities are detected, it should be
mentioned in the report whether they are consistent with
coronary anatomy or diffuse.36,37 LV diastolic function
should be also evaluated along with the valvular
apparatus.46,47 RV size and function, including a comprehen-
sive estimate of the probability of pulmonary hypertension,
are an integral part of any TTE.46,48 Abnormalities in pulmo-
nary haemodynamic should be viewed and interpreted in
the context of LV dysfunction and valvular abnormalities
and also in the perspective of lung disease (both
Figure 1 Signs and symptoms associated with chronic lung or heart involvement (prevalent cause or mixed components). COVID-19, coronavirus dis-
ease 2019; CT, computed tomography; CV, cardiovascular; HF, heart failure; PAPs, pulmonary artery pressures; Tn, high-sensitivity cardiac troponin T/I.
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parenchymal and vascular). In particular, integration of mea-
surement of LV systolic and diastolic function, of RV size,
morphology, and function, is needed to attribute increased
pulmonary artery pressure to either parenchymal or vascular
lung disease.49
Lung ultrasound
The COVID-19 pandemic has created a huge interest in lung
ultrasound. Its use is rational during the acute course of the
disease provided that a standardized approach is used, such
as the BLUE protocol.50,51 The role of lung ultrasound in
ruling out chronic lung outcomes of COVID-19 is currently
debatable.52 Moreover, it is useful when assessing HF,
haemodynamic severity, and guide management.53,54
Nevertheless, there are no robust data on its accuracy as a
diagnostic tool, its real prognostic relevance, and cut-off
values to be used.
Chest computed tomography scan
Chest computer tomography (CT) may be used as a compre-
hensive, non-invasive imaging modality, which allows for
the evaluation of lung parenchyma, and pulmonary and
coronary arteries both in the acute and subacute setting.43
Various imaging findings on chest CT have been reported at
initial presentation.55 Moreover, multiple studies categorized
COVID-19 CT findings into several stages based on time since
the onset of symptoms. These were classified into four main
successive stages: early, intermediate, and late and a fourth
restoration stage.56,57 Dual-energy CT may be useful not only
for the evaluation of lung perfusion abnormalities in
COVID-19 patients in the acute setting but also to monitor
lung sequelae in follow-up scans.58
The role of CT in the assessment of both long-term
parenchymal and vascular pulmonary disease is well
consolidated.59–61 Some studies showed that imaging of myo-
cardial fibrosis by CT is feasible with good agreement with
CMR. However, further larger studies are warranted before
its implementation in the clinical arena. Coronary computed
tomography angiography is used considering its diagnostic
accuracy, particularly its excellent negative predictive value.43
Cardiovascular magnetic resonance
The indications for CMR in the assessment of the late clini-
cal phase of COVID-19 include accurate assessment of
chamber size and function, and detection of ischaemia,
myocardial infarction, myocarditis, and stress cardiomyopa-
thy. Referrals for CMR in this setting should be thus guided
by its potential impact on patient management.41 While
clinical indications to CMR in the late COVID-19 phase, to
date, are not different from those previously recommended,
specific technical and safety suggestions have been pro-
posed as guidance in the acute (as well as in the convales-
cent phase).42
Long-term coronavirus disease 2019-
related increased cardiovascular risk
Besides the direct effects of COVID-19 on heart, vessels, lung,
and other several tissues, the SARS-CoV-2 infection and its se-
quelae may have an impact on other various risk factors
leading, in turn, to late symptoms and increased CV risk
(Figure 2). Prolonged inflammatory state, hypercoagulability,
dyslipidaemia induced or worsened by immunosuppressive
treatment, depression, and post-COVID-19 sarcopenia, which
may induce or worsen frailty, are adjunct risk factors for CV in
post-COVID-19 patients.
Micro-inflammatory state and altered immune activation
are closely related to atherosclerosis formation and vascular
events.62 Neutrophil-mediated necroinflammation, endothe-
lial injury, and the shift of intracellular and intra-tissues path-
ways towards inflammation-associated vascular pathology
are key step in COVID-19 tissue damage, and it has been pos-
tulated that COVID-19-related persistence of symptoms could
be in relationship with systemic coagulopathies and vascular
wall deterioration, resulting in dysregulated neutrophil extra-
cellular trap biology.63–66
Indeed, COVID-19-linked multi-morbidity such as HF,
renal failure, diarrhoea, neurological symptoms, and/or
sarcopenia due to malnutrition and inactivity during the
acute phase, particularly if a hospitalization was required,
together with social isolation, loneliness, and depression
are frailty-related conditions.67 Effectively, depression,
anxiety, and sleep disturbances are frequent in COVID-19
patients.68,69
Frailty confers increased risk for CV disease.70 The frail sta-
tus, being a dynamic phenomenon, may become overt or
worsen during COVID-19, and therefore, the post-COVID-19
period may expose further these patients to increased CV risk
burden.
Currently, there is no evidence available of potential
influences of these transient or permanent adjunct risk
factors on CV events. However, careful attention should
be paid to consider and treat the various faceted daily life
changes conveyed by COVID-19. Moreover, due to the com-
plex clinical characteristics of the disease, the involvement
on various organs and systems, and different social implica-
tions, a multidisciplinary approach to COVID-19 sequelae is
warranted. A widespread vaccination is warranted to pre-
vent CV events in both the CV diseased population and in
healthy subjects.
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Pharmacological cardiovascular
treatments in the late phase of
coronavirus disease 2019
In the late phase of COVID-19, both CV treatments for heart
and vessels diseases diagnosed prior to acute COVID-19 or
occurring during the acute phase should be continued as in
usual care.7 However, some pharmacological treatments have
been highlighted as potentially harmful in COVID-19 patients,
whereas the need and timing of anticoagulation treatment is
debated.
The first warning was focused on angiotensin-converting
enzyme (ACE) 2 as a potential entry receptor for SARS-CoV-
2 infection. ACE2 is known to degrade angiotensin (Ang) II
and to generate Ang-(1–7), which antagonizes the effects of
Ang II action, which is part of the beneficial effects of these
drugs. Because renin–angiotensin–aldosterone system block-
ade by ACE inhibitors, Ang II type 1 receptor antagonists,
and mineralocorticoid antagonists, as well as statins, enhance
ACE2, these treatments have been regarded during the first
phase of pandemic as potentially able to increase susceptibil-
ity to SARS-CoV-2 infection and severity of the disease.71,72 A
delicate balance between ACE2, metalloproteinase domain
17, and transmembrane protease serine 2 interactions in
each specific pathophysiological condition appears as a criti-
cal key factor in the interplay with SARS-CoV-2.73 However,
experimental data have promptly overcome these alerts,
and several scientific societies suggested avoiding drug
changes or discontinuation in patients assuming renin–angio-
tensin–aldosterone system blocking drugs.74–77
Life-threatening arrhythmias occurrence in COVID-19 may
be due to specific drugs and to drug-to-drug interactions
added on top of myocardial damage and electrolyte/volume
imbalance. These stimuli are more relevant in the acute
phase of the disease.78,79
According to the last edition of the European Society of Car-
diology guidelines for pulmonary embolism, all patients with
pulmonary embolism should be treated with anticoagulants
for at least 3 months.80 Beyond this period, the balance be-
tween the risk of VTE recurrence and that of bleeding should
be carefully assessed. To optimally estimate VTE recurrence
risk, each patient should be assessed for the presence of ma-
jor permanent (e.g. active cancer or antiphospholipid syn-
drome) or transient major (e.g. recent major surgery) and/
minor risk factors, checked for pulmonary hypertension, and
stratified according to the severity of acute COVID-19, in par-
ticular if thrombotic VTE occurred associated to an acute
hyperinflammatory syndrome (e.g. high levels of neutrophil/
lymphocyte ratio, markers of cytokinaemia, such as C-reactive
protein, interleukin-6, hyperferritinaemia, and signs of he-
patic injury).81 Additionally, young patients or patients with
concomitant unusual site thrombosis (such as splanchnic vein
thrombosis) should be tested for thrombophilia.
In case of patients with a permanent risk factor, such as ac-
tive cancer, anticoagulation should be prolonged indefinitely,
independently of the severity of the acute COVID-19.
However, patients with severe acute COVID-19 without
concomitant major or minor risk factors and admitted to
intensive care unit with an acute hyperinflammatory
syndrome may stop anticoagulation after 3–6 months if
pulmonary hypertension has been excluded.
Decision to stop or continue indefinitely anticoagulation in
other clinical scenario should be carefully balanced individu-
ally with the bleeding risk and decision-making process should
be made in individual-case basis,82 and prospective random-
ized trials are still needed to demonstrate potential benefits
of thromboprophylaxis intensification in post-COVID patients.
Role of e-cardiology in the evaluation
and management of chronic
coronavirus disease 2019-linked clinical
manifestations
During the current COVID-19 pandemic, e-cardiology became
extremely relevant in the field of cardiology.
Telemedicine and m-health were the most relevant
e-health facets,83 which were quickly adapted by healthcare
providers to tackle the challenge to assure healthcare service
under pandemic condition, even for COVID-19-related
chronic manifestations.
The most prominent telemedical approach for general car-
diologists was the rapid dissemination of online video consul-
tations in the outpatient setting. During March and April
2020, the number of online video consultations increased
by 600% in Germany compared with the same time frame
in 2019.84 The implementation of certificated video confer-
ence systems is easy to handle and needs only a short user
instruction. The patient needs only two technical require-
ments: (i) an end device with front camera and (ii) an
e-mail account. The online video consultation represents an
ideal tool for the follow-up of a well-known patient and
should only be used as an ‘add-on’ to reduce the number of
regular on-site visits, rather than to substitute all on-site
visits, in particular for new patients.
First experiences showed that patient’s willingness to par-
ticipate in online consultation is about 45% with increasing
tendency, even in older patients. However, if this trend to on-
line video consultation will be a sustainable development
towards digital health is unclear.85 One-third of the cardiolog-
ical outpatients still prefer on-site visits only, even under
pandemic conditions. Moreover, the pandemic has led to a
worldwide implementation of remote monitoring of cardiac
implantable electronic devices, in order to reduce the
in-office device control and reduce the risk of contagion.86,87
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Another e-cardiology approach represents telemonitoring
with a daily transfer of vital parameter. This remote patient
management model was established for recently hospital-
ized high-risk HF patients and is very beneficial under cur-
rent pandemic conditions to these patients who are also at
high risk for COVID-19. One example is the TELEMED5000-
COVID-19 study (German clinical trial register number:
DRKS00022244), which is an ongoing observational trial
including 100 patients, which survived an inpatient stay of
COVID-19. In addition to the home equipment used in
telemedicine for HF patients, all study patients will receive
a tablet with a voice-analysing app. The voice recording will
be analysed using methods of artificial intelligence and is
assumed to be a new vital parameter to quantify fatigue
and/or pulmonary congestion. Another app should support
repeated 6 min walking test in the patient’s surroundings
(Figure 3). This vital parameter could be used as a surrogate
for changing exercise capacity during the recovery period.
The follow-up period of this trial will be 1 year, and the first
results will be available in 2021.
Wearables should be envisaged in chronic cardiac patients
to continue regular monitoring, to reduce risk of transmission
due to their increased risk of infection with worse outcome,
and to diagnose COVID-19 infection promptly.88–91 Wearables
certified as medical device use allow monitoring of vital signs
such as oxygen saturation, respiratory rate, blood pressure,
body temperature, ECG (to measure QT intervals also), and
also position and movement assessment, pulmonary auscul-
tation, and cough monitoring.92 The choice to use wearables
for remote care should be shared by the patient. In conclu-
sion, e-health technologies were rapidly adapted during the
onset of the pandemic, but the hypothesis of a beneficial ef-
fect for management of chronic COVID-19-related clinical
manifestations needs to be proven (Figure 2).
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Figure 2 Late covid associated symptoms. CVD, cardiovascular disease; ICU, intensive care unit.
Figure 3 Example of a telemonitoring home equipment set to follow-up coronavirus disease 2019 patients: a tablet with a voice-analysing app using
methods of artificial intelligence and an app for recording of a repeated 6 min walk test. Further devices are an electrocardiogram, a blood pressure
device, a pulse oximeter, and a body scale. © Charité—Universitätsmedizin Berlin.
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